Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.65 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.64 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.62 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.62 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.57 |
| ▸ | CSK | P41240 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955512 | 1.00 | ENPP1 (0.65) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL2924110 | 0.99 | ENPP1 (0.64) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL4178028 | 0.94 | ENPP1 (0.67) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL30408709 | 0.94 | ENPP1 (0.67) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL18744742 | 0.94 | ENPP1 (0.67) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL4379458 | 0.93 | KDR (0.66) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL4187391 | 0.92 | ENPP1 (0.55) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| Hydrochloric Acid SCHEMBL4373335 | 0.92 | KDR (0.64) | ENPP1EHMT2EHMT1EGFRTLR9 | |
| SCHEMBL2190137 | 0.92 | ENPP1 (0.64) | ENPP1EGFRKDRFGFR1FLT1 | |
| SCHEMBL2188204 | 0.92 | ENPP1 (0.64) | ENPP1EGFRKDRFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017035170-A1 | SOLID STATE FORMS OF CEDIRANIB MALEATE | PLIVA HRVATSKA D.O.O (HR) | 2017-03-02 | — | — | WO | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-1553097-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | ENPP1 2575/4885EHMT2 4727/4885EHMT1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.